Feasibility and therapeutic potential of 177Lu–fibroblast activation protein inhibitor–46 for patients with relapsed or refractory cancers: a preliminary study M Assadi, SJ Rekabpour, E Jafari, GA Divband, B Nikkholgh, H Amini, ... Clinical nuclear medicine 46 (11), e523-e530, 2021 | 84 | 2021 |
Targeted palliative radionuclide therapy for metastatic bone pain R Manafi-Farid, F Masoumi, G Divband, B Saidi, B Ataeinia, F Hertel, ... Journal of clinical medicine 9 (8), 2622, 2020 | 43 | 2020 |
A case of COVID-19 lung infection first detected by [18F] FDG PET-CT H Amini, G Divband, Z Montahaei, T Dehghani, H Kaviani, Z Adinehpour, ... European Journal of Nuclear Medicine and Molecular Imaging 47, 1771-1772, 2020 | 21 | 2020 |
Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer N Vahidfar, M Fallahpoor, S Farzanehfar, G Divband, H Ahmadzadehfar Journal of Radioanalytical and Nuclear Chemistry 322, 237-248, 2019 | 16 | 2019 |
177Lu-EDTMP for Metastatic Bone Pain Palliation: A Systematic Review and Meta-Analysis E Askari, S Harsini, N Vahidfar, G Divband, R Sadeghi Cancer biotherapy & radiopharmaceuticals 36 (5), 383-390, 2021 | 14 | 2021 |
A comparison of body mass index and percent body fat as predictors of cardiovascular risk factors MGM HoseinSheibani, HabibollahEsmaeili, MaryamTayefide, MaryamSaberi ... Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2018 | 14* | 2018 |
Rhenium‐188 radiosynovectomy for chronic haemophilic synovitis: Evaluation of its safety and efficacy in haemophilic patients AR Kachooei, A Heidari, G Divband, ME Zandinezhad, A Mousavian, ... Haemophilia 26 (1), 142-150, 2020 | 12 | 2020 |
Bone metastasis in prostate cancer: bone scan versus PET imaging N Mohseninia, N Zamani-Siahkali, S Harsini, G Divband, C Pirich, ... Seminars in Nuclear Medicine, 2023 | 11 | 2023 |
Predictive and prognostic potential of pretreatment 68Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer … M Assadi, R Manafi-Farid, E Jafari, A Keshavarz, GA Divband, MM Moradi, ... Frontiers in Oncology 12, 1066926, 2022 | 11 | 2022 |
68Ga-FAPI-46 PET/CT in a metastatic castration-resistant prostate cancer patient with low PSMA expression K Aryana, R Manafi-Farid, H Amini, G Divband, SZ Moghadam Clinical Nuclear Medicine 47 (11), 972-973, 2022 | 11 | 2022 |
Favorable response after only one cycle of peptide receptor radionuclide therapy with 177Lu-DOTATATE in a patient with metastatic Merkel cell carcinoma SZ Moghadam, G Divband, S Shakeri, K Aryana Clinical Nuclear Medicine 44 (8), 650-652, 2019 | 11 | 2019 |
Fibroblast activation protein inhibitor imaging and therapy in a patient with multiple endocrine neoplasia type 2A syndrome S Barashki, G Divband, E Askari, H Amini, K Aryana Clinical Nuclear Medicine 47 (3), e284-e286, 2022 | 9 | 2022 |
Efficacy, safety and prognostic factors affecting overall survival among metastatic prostate cancer patients undergoing treatment with 177Lu-PSMA-617: a single center study SZ Moghadam, E Askari, G Divband, S Shakeri, K Aryana Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 41 …, 2022 | 7 | 2022 |
Torsion of the undescended testis detected by 99mTc testicular scintigraphy: a case report H Shayegani, G Divband, M Tavakkoli, M Banihasan, R Sadeghi Nuclear Medicine Review 19 (B), 24-25, 2016 | 5 | 2016 |
68Ga-FAPI-46 and 18F-FDG in advanced metastatic pancreatic cancer F Kaghazchi, G Divband, H Amini, Z Adinehpour, RA Aghdam Clinical Nuclear Medicine 47 (10), e666-e669, 2022 | 4 | 2022 |
A comparison of body mass index and body fat percentage for predicting cardiovascular disease risk H Sheibani, M Saberi-Karimian, H Esmaily, M Mouhebati, ... Translational Metabolic Syndrome Research 3, 29-34, 2020 | 4 | 2020 |
99m Tc-Octreotide-avid brain mass in a patient with poorly differentiated papillary thyroid carcinoma, hope in despair S Shakeri, P Jahanpanah, G Divband, T Massoudi, K Aryana Nuclear Medicine Review 23 (1), 49-50, 2020 | 3 | 2020 |
177Lu–Prostate-Specific Membrane Antigen Super Scan and Good Response Even After 1 Cycle of Radioligand Therapy K Aryana, R Salek, G Divband Clinical Nuclear Medicine 43 (4), 273-275, 2018 | 3 | 2018 |
Development and evaluation of 89Zr-trastuzumab for clinical applications F Mohammadpour-Ghazi, H Yousefnia, GA Divband, S Zolghadri, ... Asia Oceania Journal of Nuclear Medicine and Biology 11 (2), 135, 2023 | 2 | 2023 |
Amino acid extravasation: a rare red flag to keep in mind during peptide receptor radioligand therapy (PRRT) with [177Lu] Lu-DOTATATE G Divband, SH Alavi, Z Adinehpour, F Kalantari, ... Nucl. Med. Rev. Cent. East. Eur 25, 136-137, 2022 | 2 | 2022 |